Deucravacitinib

Phase 1Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pyoderma Gangrenosum

Conditions

Pyoderma Gangrenosum

Trial Timeline

Apr 29, 2024 → Apr 29, 2024

NCT ID

NCT05821374

About Deucravacitinib

Deucravacitinib is a phase 1 stage product being developed by Bristol Myers Squibb for Pyoderma Gangrenosum. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05821374. Target conditions include Pyoderma Gangrenosum.

What happened to similar drugs?

1 of 6 similar drugs in Pyoderma Gangrenosum were approved

Approved (1) Terminated (5) Active (1)

🔄adalimumabAbbViePhase 3

✅sisomicinMerckApproved

❌gevokizumab + Placebo + gevokizumab open-labelXOMAPhase 3

❌gevokizumabXOMAPhase 3

❌gevokizumab + Placebo + gevokizumab open-labelXOMAPhase 3

❌vilobelimab + PlaceboInflaRxPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06979453	Phase 3	Recruiting	Dec 3, 2025	Aug 12, 2034	Plaque Psoriasis
NCT07256015	Pre-clinical	Recruiting	Aug 5, 2025	Aug 5, 2027	Psoriasis
NCT06869551	Phase 3	Recruiting	Mar 13, 2025	Mar 4, 2031	Juvenile Psoriatic Arthritis
NCT06725264	Phase 2	Withdrawn	Mar 1, 2025	Jun 1, 2026	Sarcoidosis
NCT06701513	Pre-clinical	Recruiting	Jan 29, 2025	Apr 30, 2028	Psoriasis
NCT06512337	Pre-clinical	Recruiting	Jan 20, 2025	Aug 31, 2026	Plaque Psoriasis
NCT06566768	Phase 1	Completed	Oct 7, 2024	Jun 13, 2025	Healthy Participants
NCT06258668	Pre-clinical	Recruiting	Aug 21, 2024	Sep 30, 2028	Moderate-to-severe Plaque Psoriasis
NCT06476834	Approved	Completed	Jun 24, 2024	Nov 2, 2024	Healthy Volunteers
NCT05821374	Phase 1	Withdrawn	Apr 29, 2024	Apr 29, 2024	Pyoderma Gangrenosum
NCT06091956	Phase 2	Completed	Nov 7, 2023	Dec 24, 2024	Lichen Planopilaris
NCT05858645	Approved	Recruiting	Oct 1, 2023	Jun 1, 2026	Psoriasis Vulgaris
NCT05946941	Phase 3	Active	Sep 11, 2023	Nov 16, 2028	Sjögren's Syndrome
NCT06104644	Pre-clinical	Active	Apr 13, 2023	May 31, 2030	Plaque Psoriasis
NCT05701995	Approved	Completed	Jan 31, 2023	May 29, 2025	Psoriasis
NCT05617677	Phase 3	Active	Jan 12, 2023	Nov 13, 2028	Systemic Lupus Erythematosus
NCT05620407	Phase 3	Active	Jan 12, 2023	Nov 13, 2028	Systemic Lupus Erythematosus
NCT05556265	Phase 2	Terminated	Nov 8, 2022	May 16, 2024	Alopecia Areata
NCT05478499	Approved	Completed	Oct 6, 2022	Oct 17, 2024	Psoriasis
NCT04908202	Phase 3	Active	Jul 13, 2021	Jun 10, 2027	Psoriatic Arthritis

Competing Products

11 competing products in Pyoderma Gangrenosum

See all competitors

Product	Company	Stage	Hype Score
Ixekizumab	Eli Lilly	Phase 2	35
adalimumab	AbbVie	Phase 3	40
sisomicin	Merck	Approved	35
secukinumab 150 mg (2 injections per dose	Novartis	Phase 2	27
Secukinumab	Novartis	Phase 1/2	32
gevokizumab	XOMA	Phase 2	25
gevokizumab + Placebo + gevokizumab open-label	XOMA	Phase 3	22
gevokizumab	XOMA	Phase 3	22
gevokizumab + Placebo + gevokizumab open-label	XOMA	Phase 3	22
vilobelimab + Placebo	InflaRx	Phase 3	22
vilobelimab	InflaRx	Phase 2	25